Live Cell Encapsulation Market | Industry Application Reshaping The Global Market

Pune, India, 2020-Apr-15 — /EPR Network/ —

Growth in the live cell encapsulation market is primarily driven by factors such as the increasing public-private investments to support product development, increasing research to establish the clinical efficacy of cell encapsulation technologies, and rising public awareness related to the clinical role of encapsulated cells in disease management.

Live Cell Encapsulation Market by Technique (Dripping (Simple, Electrostatic), Coaxial Airflow, Liquid Jet), Polymer (Alginate, Chitosan, Silica, Cellulose Sulfate), Application (Probiotics, Transplant, Drug Delivery, Research).

The live cell encapsulation market is projected to grow to USD 303 million by 2024 from USD 250 million in 2018, at a CAGR of 3.2%.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218019375

Drug delivery are expected to be the largest contributor to the live cell encapsulation market.

Cell encapsulation is undertaken for the manufacturing of tablets, capsules, and parenteral dosage forms for effective drug delivery. The growth of this segment includes the increasing adoption of cell encapsulation for drug delivery is mainly due to its procedural benefits (such as improved efficacy, reduced toxicity, and improved patient compliance & convenience).

Geographical Growth Analysis:

North America is one of the major revenue-generating regions in the live cell encapsulation market. The increasing public-private investments in the live cell encapsulation industry in the US and Canada, ongoing technological advancements in live cell encapsulation, and the presence of major market players in the region are the major factors driving the growth of the live cell encapsulation market in North America.

Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=218019375

BioTime, Inc. (US), Viacyte, Inc. (US), and Living Cell Technologies Ltd. (Australia) were the top three players in the live cell encapsulation market. Other prominent players operating in this market include Sigilon Therapeutics, Inc. (US), Evonik Industries (Germany), BÜCHI Labortechnik AG (Germany), Blacktrace Holdings Ltd (UK), and Sernova Corporation (Canada), among others. Furthermore, the key players in the developmental pipeline products in this market include Neurotech Pharmaceuticals, Inc. (US), Gloriana Therapeutics (US), Kadimastem (Israel), Beta-O2 Technologies, Inc. (Israel), Defymed (France), and Altucell, Inc. (US), among others.